We are Nalpha-FMOC-L-Glutamine CAS:71989-20-3 manufacturer and supplier in China, Pls send inquiry of to email@example.com of visit www.nbinno.com our official website should you have any interests
Chemical Name: Nalpha-FMOC-L-Glutamine
Physical and Chemical Properties:
Density: 1.332 g / cm3
Boiling point: 699.8ºC at 760 mmHg
Melting point: 220 ° C (dec.) (Lit.)
Flash point: 377.1ºC
Refractive index: 1.617
Appearance: White to off-white crystalline powder
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store at 2-8ºC.Keep the container tightly closed, put it in a tight dispenser, and store in a cool, dry place.
Application:N2-Fmoc-L-glutamine is an N-Fmoc-protected form of L-Glutamine. L-Glutamine is a non-essential amino acid that is important for cells that proliferate quickly in the body, such as those of the immune system. L-Glutamine is known to be especially important for the gut, as it helps to maintain intestinal structure and function. L-Glutamine also has protective properties against host toxicity of chemotherapy in cancer patients.
Related News: Slower growth in pesticide intermediates weighed on industrial business. In the first three quarters, the company’s operating income was 2.977 billion yuan, a year-on-year increase of 2.57%.3-cloro-6- (trifluorometil) piridazina CAS:258506-68-2 More serious cases could lead to potentially deadly conditions such as pneumonia and kidney failure, with the former having been reported among some patients in China.111721-75-6 More serious cases could lead to potentially deadly conditions such as pneumonia and kidney failure, with the former having been reported among some patients in China.3-BROMO-2-FLUORO-4-IODOPYRIDINE CAS:884494-52-4 More serious cases could lead to potentially deadly conditions such as pneumonia and kidney failure, with the former having been reported among some patients in China.The acquired pharmaceutical intermediates business will be renamed Corden Pharma Switzerland LLC and will operate as part of ICIG’s pharmaceutical business within the Corden Pharma platform. The companies’ goal is to close the transaction during the first quarter of 2011. Financial terms are not disclosed.